Dr. Susan Galbraith

So I think the field is open.

It'd be interesting to see the data as they evolve.

Yeah.

Okay.

So a couple of comments that I would make, first of all, one is that, you know, there have been three trials now in this setting, but the design of the third trial, the Auburn study that wasn't positive, I think was different in terms of the patient population that enrolled.

So with the Patumac study, we focused on the higher risk patient population.

It

you know, with higher risk features.

And it was good to see that, you know, you have seen this reduction in event-free survivors or patients that are coming in that have got high risk disease and risk of having recurrent transurethral resections of bladder cancer.

And, you know, what that leads to over time is

increasing risk that they do have to go on to a cystectomy because they're likely to have progression to muscle invasive disease.

And obviously, you're right, cystectomy is a life-changing major surgery.

So in Potomac, we included high-grade patients with TA or T1 and or carcinoma in situ, which is multiple and recurrent and large.

And I think that identifies that higher risk patient population.

And so it's encouraging to see the early separation that occurs with the event free survival.

So it means that patients don't have to have another resection of disease and few of them will go on to have a recommendation for cystectomy.

Now, with the size of the study that we've seen so far, what we haven't yet shown statistically significantly is an absolute reduction in the rate of cystectomy.

I think we'll have to wait for longer term follow up for that.

But that is the goal of what we're looking to do in both non-muscle invasive disease.

And I think in the